9,27 Although the number of patients who had received prior adjuvant or neoadjuvant chemotherapy with trastuzumab was small, the progression-free survival benefit of pertuzumab plus trastuzumab ...

Patients were randomly assigned to neoadjuvant T-DM1+P or TCH+P every 3 weeks for six cycles. Patients who received T-DM1+P continued adjuvant T-DM1+P, and patients who received TCH+P received ...

Neoadjuvant trastuzumab (H), pertuzumab (P), and chemotherapy versus trastuzumab emtansine (T-DM1) and P in human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC): Final outcome ...

9 Dual HER2 blockade with pertuzumab and trastuzumab is the standard of care as first-line therapy for patients with advanced HER2-positive disease. As part of a neoadjuvant regimen, pertuzumab ...

NEW ORLEANS — Results from the I-SPY 2 trial show that a new presurgery (neoadjuvant) combination of trastuzumab emtansine (T-DM1; Kadcyla, Genentech, Inc) and pertuzumab (Perjeta, Genentech ...

Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open ...

The term neoadjuvant means that a person typically ... A doctor may recommend both pertuzumab and trastuzumab if a person has a higher risk of recurrent breast cancer or metastases in the lymph ...

However, combination therapy involving trastuzumab and pertuzumab ... completion of the full course of treatment if pertuzumab is added to the neoadjuvant regimen. "If a patient is otherwise ...

Arm C received docetaxel and carboplatin plus trastuzumab and pertuzumab. After patients were treated with neoadjuvant therapy, they underwent surgery and continued on trastu-zumab until they ...

1.1 Pertuzumab, in combination with trastuzumab and chemotherapy, is recommended, within its marketing authorisation, as an option for the neoadjuvant treatment of adults with human epidermal growth ...